RefleXion Medical will feature its groundbreaking RefleXion X1 with SCINTIX biology-guided radiotherapy at ASTRO 2023. Researchers will present 19 scientific findings supporting the effectiveness of SCINTIX therapy, highlighting its precision in treating moving targets, successful human trials, and error mitigation using the X1 with SCINTIX technology. This marks a significant step as they begin patient treatments across the U.S. Dr. Shervin “Sean” Shirvani, Chief Medical Officer at RefleXion, expressed enthusiasm for the growing body of evidence affirming SCINTIX therapy’s efficacy.
RefleXion Medical, a pioneering player in the field of therapeutic oncology, is proud to announce its participation in the American Society for Radiation Oncology (ASTRO) Annual Meeting from October 1 to 4, 2023, in San Diego, at BOOTH # 2831. The spotlight of the event will be the RefleXion X1, featuring SCINTIX biology-guided radiotherapy. Distinguished researchers from various clinical programs will unveil a wealth of new scientific insights through 19 presentations, including oral presentations and featured posters. These presentations will provide compelling evidence supporting the remarkable efficacy and practicality of SCINTIX therapy exclusively delivered via the X1 platform.
Dr. Shervin “Sean” Shirvani, M.D., M.P.H., the Chief Medical Officer at RefleXion, expressed his enthusiasm, stating, “We are immensely excited to witness the ever-growing body of evidence that unequivocally validates the efficacy of SCINTIX therapy. This comes at a pivotal time as we embark on patient treatments at multiple locations across the United States. The highlights from these presentations underscore the groundbreaking precision in treating multiple moving targets within a single session. They also divulge key insights from our successful completion of first-in-human trials and elucidate the strategies for mitigating IMRT/SBRT treatment planning errors using our state-of-the-art X1 with SCINTIX technology.”
